Improvements in clinical response between 12 and 24 weeks in patients with rheumatoid arthritis on etanercept therapy with or without methotrexate
Open Access
- 1 October 2008
- journal article
- research article
- Published by BMJ in Annals Of The Rheumatic Diseases
- Vol. 67 (10), 1444-1447
- https://doi.org/10.1136/ard.2008.094524
Abstract
Background: Whereas many patients respond quickly to treatment with tumour necrosis factor (TNF) inhibitors, some patients may experience significant but delayed responses. Objective: To evaluate the clinical response between 12 and 24 weeks in subjects with rheumatoid arthritis from the Trial of Etanercept and Methotrexate with Radiographic Patient Outcomes. Methods: Clinical response was assessed at 24 weeks in 12-week non-responders, according to American College of Rheumatology (ACR) response criteria. The proportion of subjects who successfully maintained response to 52 weeks was analysed, as were radiographic outcomes. Results: Data from 682 subjects were included in the analysis. Non and partial responders in all three groups (etanercept, methotrexate and etanercept plus methotrexate) at week 12 showed an improvement in responses at week 24. Over 80% of the week 24 ACR20/50/70 responders in the etanercept plus methotrexate arm sustained their response to 52 weeks. In the etanercept arms, a delayed clinical response was not associated with increased radiographic progression at week 52. Conclusion: A significant proportion of non and partial responders to etanercept with or without methotrexate therapy at week 12 achieved a good clinical response or improved their overall clinical response at week 24. Discontinuing TNF inhibitor therapy at 12 weeks may be premature in some rheumatoid arthritis patients.Keywords
This publication has 14 references indexed in Scilit:
- Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2006Annals Of The Rheumatic Diseases, 2006
- Disconnect between inflammation and joint destruction after treatment with etanercept plus methotrexate: Results from the trial of etanercept and methotrexate with radiographic and patient outcomesArthritis & Rheumatism, 2006
- Rituximab for rheumatoid arthritis refractory to anti–tumor necrosis factor therapy: Results of a multicenter, randomized, double‐blind, placebo‐controlled, phase III trial evaluating primary efficacy and safety at twenty‐four weeksArthritis & Rheumatism, 2006
- Comparison of etanercept and methotrexate, alone and combined, in the treatment of rheumatoid arthritis: Two‐year clinical and radiographic results from the TEMPO study, a double‐blind, randomized trialArthritis & Rheumatism, 2006
- Update on the British Society for Rheumatology guidelines for prescribing TNF blockers in adults with rheumatoid arthritis (update of previous guidelines of April 2001)Rheumatology, 2005
- Current managementActa Orthopaedica, 2005
- Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trialThe Lancet, 2004
- WHO Collaborating Centre consensus meeting on anti-cytokine therapy in rheumatoid arthritisRheumatology, 2001
- A Comparison of Etanercept and Methotrexate in Patients with Early Rheumatoid ArthritisNew England Journal of Medicine, 2000
- A Trial of Etanercept, a Recombinant Tumor Necrosis Factor Receptor:Fc Fusion Protein, in Patients with Rheumatoid Arthritis Receiving MethotrexateNew England Journal of Medicine, 1999